Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma

Title: Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma
Authors: Stack, Trevor; Vincent, Michael; Vahabikashi, Amir; Li, Guorong; Perkumas, Kristin M.; Stamer, W. Daniel; Johnson, Mark; Scott, Evan
Contributors: National Institutes of Health
Source: Small ; volume 16, issue 43 ; ISSN 1613-6810 1613-6829
Publisher Information: Wiley
Publication Year: 2020
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: Increased stiffness of the Schlemm's canal (SC) endothelium in the aqueous humor outflow pathways has been associated with elevated intraocular pressure (IOP) in glaucoma. Novel treatments that relax this endothelium, such as actin depolymerizers and rho kinase inhibitors, are in development. Unfortunately, these treatments have undesirable off‐target effects and a lower than desired potency. To address these issues, a targeted PEG ‐b‐ PPS micelle loaded with actin depolymerizer latrunculin A (tLatA‐MC) is developed. Targeting of SC cells is achieved by modifying the micelle surface with a high affinity peptide that binds the VEGFR3/FLT4 receptor, a lymphatic lineage marker found to be highly expressed by SC cells relative to other ocular cells. During in vitro optimization, increasing the peptide surface density increased micellar uptake in SC cells while unexpectedly decreasing uptake by human umbilical vein endothelial cells (HUVEC). The functional efficacy of tLatA‐MC, as measured by decreased SC cell stiffness compared to non‐targeted micelles (ntLatA‐MC) or targeted blank micelles (tBL‐MC), is verified using atomic force microscopy. tLatA‐MC reduced IOP in an in vivo mouse model by 30–50%. The results validate the use of a cell‐softening nanotherapy to selectively modulate stiffness of SC cells for therapeutic reduction of IOP and treatment of glaucoma.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1002/smll.202004205
Availability: https://doi.org/10.1002/smll.202004205; https://onlinelibrary.wiley.com/doi/pdf/10.1002/smll.202004205; https://onlinelibrary.wiley.com/doi/full-xml/10.1002/smll.202004205
Rights: http://onlinelibrary.wiley.com/termsAndConditions#vor
Accession Number: edsbas.C0D8C0C
Database: BASE